Literature DB >> 16025095

Drug resistance in brain diseases and the role of drug efflux transporters.

Wolfgang Löscher1, Heidrun Potschka.   

Abstract

Resistance to drug treatment is an important hurdle in the therapy of many brain disorders, including brain cancer, epilepsy, schizophrenia, depression and infection of the brain with HIV. Consequently, there is a pressing need to develop new and more effective treatment strategies. Mechanisms of resistance that operate in cancer and infectious diseases might also be relevant in drug-resistant brain disorders. In particular, drug efflux transporters that are expressed at the blood-brain barrier limit the ability of many drugs to access the brain. There is increasing evidence that drug efflux transporters have an important role in drug-resistant brain disorders, and this information should allow more efficacious treatment strategies to be developed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16025095     DOI: 10.1038/nrn1728

Source DB:  PubMed          Journal:  Nat Rev Neurosci        ISSN: 1471-003X            Impact factor:   34.870


  243 in total

Review 1.  A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury.

Authors:  Kevin W McConeghy; Jimmi Hatton; Lindsey Hughes; Aaron M Cook
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

2.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

3.  Association between ABCB1-T1236C polymorphism and drug-resistant epilepsy in Iranian female patients.

Authors:  Mehri Maleki; Mohammad Sayyah; Fatemeh Kamgarpour; Morteza Karimipoor; Aida Arab; Anahita Rajabi; Kourosh Gharagozli; Ahmad Reza Shamshiri; Esmaeil Shahsavand Ananloo
Journal:  Iran Biomed J       Date:  2010-07

4.  The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).

Authors:  Pavitra Kannan; Sanjay Telu; Suneet Shukla; Suresh V Ambudkar; Victor W Pike; Christer Halldin; Michael M Gottesman; Robert B Innis; Matthew D Hall
Journal:  ACS Chem Neurosci       Date:  2010-10-21       Impact factor: 4.418

Review 5.  Imaging of P-glycoprotein function and expression to elucidate mechanisms of pharmacoresistance in epilepsy.

Authors:  Wolfgang Löscher; Oliver Langer
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

Review 6.  Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.

Authors:  Megan O Jacus; Vinay M Daryani; K Elaine Harstead; Yogesh T Patel; Stacy L Throm; Clinton F Stewart
Journal:  Clin Pharmacokinet       Date:  2016-03       Impact factor: 6.447

7.  A high-content assay strategy for the identification and profiling of ABCG2 modulators in live cells.

Authors:  Christophe Antczak; Boyoung Wee; Constantin Radu; Bhavneet Bhinder; Eric C Holland; Hakim Djaballah
Journal:  Assay Drug Dev Technol       Date:  2013-08-30       Impact factor: 1.738

8.  Distribution pattern of mirtazapine and normirtazapine in blood and CSF.

Authors:  Michael Paulzen; Gerhard Gründer; Simone C Tauber; Tanja Veselinovic; Christoph Hiemke; Sarah E Groppe
Journal:  Psychopharmacology (Berl)       Date:  2014-08-23       Impact factor: 4.530

9.  Blood-brain barrier damage and brain penetration of antiepileptic drugs: role of serum proteins and brain edema.

Authors:  Nicola Marchi; Giulia Betto; Vincent Fazio; Quinyuan Fan; Chaitali Ghosh; Andre Machado; Damir Janigro
Journal:  Epilepsia       Date:  2009-01-21       Impact factor: 5.864

10.  Exploring the Carbamazepine Interaction with Human Pregnane X Receptor and Effect on ABCC2 Using in Vitro and in Silico Approach.

Authors:  Gurpreet K Grewal; Khuraijam D Singh; Neha Kanojia; Chitra Rawat; Samiksha Kukal; Ajay Jajodia; Anshika Singhal; Richa Misra; Selvaraman Nagamani; Karthikeyan Muthusamy; Ritushree Kukreti
Journal:  Pharm Res       Date:  2017-04-21       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.